Anti-VLA-4 monoclonal antibody TA-2

Drug Profile

Anti-VLA-4 monoclonal antibody TA-2

Latest Information Update: 26 Apr 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dalhousie University; McGill University
  • Class Monoclonal antibodies
  • Mechanism of Action Integrin alpha4beta1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Asthma; Rheumatoid arthritis; Transplant rejection

Most Recent Events

  • 10 Aug 2000 No-Development-Reported for Rheumatoid arthritis in Germany (Unknown route)
  • 10 Aug 2000 No-Development-Reported for Transplant rejection in Canada (Unknown route)
  • 10 Aug 2000 Preclinical development for Asthma in Canada (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top